NO20072542L - Pyrimidinderivat kondensert med ikke-aromatisk ring - Google Patents

Pyrimidinderivat kondensert med ikke-aromatisk ring

Info

Publication number: NO20072542L
Authority: NO; Norway
Prior art keywords: insulin; aromatic ring; pyrimidine derivative; diabetes; compounds
Prior art date: 2004-10-20

Application number

NO20072542A

Other languages

English (en)

Norwegian (no)

Inventor

Yasuhiro Yonetoku

Kenji Negoro

Kenichi Onda

Masahiko Hayakawa

Daisuke Sasuga

Takahiro Nigawara

Kazuhiko Iikubo

Hiroyuki Moritomo

Shigeru Yoshida

Takahide Ohishi

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-20

Filing date

2007-05-18

Publication date

2007-07-18

2007-05-18 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2007-07-18 Publication of NO20072542L publication Critical patent/NO20072542L/no

Links

125000006574 non-aromatic ring group Chemical group 0.000 title abstract 2
150000003230 pyrimidines Chemical class 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
239000004480 active ingredient Substances 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
201000001421 hyperglycemia Diseases 0.000 abstract 1
230000001965 increasing effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

NO20072542A 2004-10-20 2007-05-18 Pyrimidinderivat kondensert med ikke-aromatisk ring NO20072542L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2004305374		2004-10-20
PCT/JP2005/019000 WO2006043490A1 (ja)	2004-10-20	2005-10-17	非芳香環縮合ピリミジン誘導体

Publications (1)

Publication Number	Publication Date
NO20072542L true NO20072542L (no)	2007-07-18

Family

ID=36202906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072542A NO20072542L (no)	2004-10-20	2007-05-18	Pyrimidinderivat kondensert med ikke-aromatisk ring

Country Status (15)

Country	Link
US (1)	US7947690B2 (pt)
EP (1)	EP1803710A4 (pt)
JP (1)	JP4775767B2 (pt)
KR (1)	KR20070084035A (pt)
CN (1)	CN101044123B (pt)
AU (1)	AU2005297743A1 (pt)
BR (1)	BRPI0516237A (pt)
CA (1)	CA2584666C (pt)
IL (1)	IL182641A0 (pt)
MX (1)	MX2007004769A (pt)
NO (1)	NO20072542L (pt)
RU (1)	RU2007118653A (pt)
TW (1)	TW200621257A (pt)
WO (1)	WO2006043490A1 (pt)
ZA (1)	ZA200703947B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1577816A3 (en) *	1996-09-04	2006-08-02	Intertrust Technologies Corp.	Trusted infrastructure support systems, methods and techniques for secure electronic commerce and rights management
CA2512899A1 (en)	2003-01-14	2004-08-05	Arena Pharmaceuticals Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN103497173A (zh) *	2006-03-31	2014-01-08	财团法人乙卯研究所	具有杂环的新化合物
EP1971862B1 (en)	2006-04-11	2010-11-10	Arena Pharmaceuticals, Inc.	Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DE602007011628D1 (de) *	2006-07-06	2011-02-10	Array Biopharma Inc	Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
SI2054418T1 (sl)	2006-07-06	2012-02-29	Array Biopharma Inc	Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
US8063050B2 (en)	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2049500B1 (en) *	2006-07-06	2011-09-07	Array Biopharma, Inc.	Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
AU2008267724A1 (en) *	2007-06-28	2008-12-31	Merck Frosst Canada Ltd	Substituted fused pyrimidines as antagonists of GPR105 activity
CN101801955B (zh) *	2007-07-05	2013-05-08	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2009204019B2 (en)	2008-01-09	2014-02-20	Array Biopharma Inc.	Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
EP2247578B1 (en)	2008-01-09	2013-05-22	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
EP2108960A1 (en)	2008-04-07	2009-10-14	Arena Pharmaceuticals, Inc.	Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
JP2011529920A (ja) *	2008-07-31	2011-12-15	ジェネンテック，インコーポレイテッド	ピリミジン化合物、組成物及び使用方法
US20100331305A1 (en) *	2009-06-24	2010-12-30	Genentech, Inc.	Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
US20110021515A1 (en) *	2009-07-24	2011-01-27	Takeda Pharmaceutical Company Limited	Dihyrofuropyrmindine compounds
CN102020657A (zh) *	2009-09-11	2011-04-20	上海艾力斯医药科技有限公司	稠合杂芳基衍生物、制备方法及其应用
JP5572715B2 (ja) *	2009-11-12	2014-08-13	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法
CN102711766B (zh) *	2009-11-12	2014-06-04	霍夫曼-拉罗奇有限公司	N-9-取代的嘌呤化合物、组合物和使用方法
CN103068818B (zh) *	2010-08-26	2014-11-19	兴和株式会社	异喹啉衍生物或其盐的新制造方法
CN103539791B (zh)	2010-09-22	2017-01-11	艾尼纳制药公司	Gpr119 受体调节剂和对与其相关的障碍的治疗
WO2012099581A1 (en)	2011-01-19	2012-07-26	Takeda Pharmaceutical Company Limited	Dihydrofuropyrimidine compounds
KR102021157B1 (ko)	2011-04-01	2019-09-11	제넨테크, 인크.	Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
RU2013148817A (ru)	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений-ингибиторов акт и мек и способы их применения
CN102875567B (zh) *	2011-07-15	2015-03-11	天津药物研究院	一类含哌嗪化合物、制备及用途
WO2014124860A1 (en) *	2013-02-14	2014-08-21	Boehringer Ingelheim International Gmbh	Specific pde4b-inhibitors for the treatment of diabetes mellitus
TW201512189A (zh)	2013-04-16	2015-04-01	Gruenenthal Chemie	新型被取代之嘧啶縮合化合物
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
WO2016209809A1 (en)	2015-06-22	2016-12-29	Arena Pharmaceuticals, Inc.	Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
US11534424B2 (en)	2017-02-16	2022-12-27	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
AU2018274599B9 (en)	2017-05-22	2022-04-07	Topadur Pharma Ag	Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
ES2987794T3 (es)	2018-06-06	2024-11-18	Arena Pharm Inc	Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
JP2025505163A (ja) *	2022-02-02	2025-02-21	ザ・カトリック・ユニヴェルシテイト・ルーバン	Ｙａｐ／ｔａｚ－ｔｅａｄを阻害するためのテトラヒドロピリドピリミジン及び関連類似体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1470336A1 (de)	1962-07-04	1969-03-20	Thomae Gmbh Dr K	Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
DE3888215T2 (de) *	1987-01-21	1994-09-08	Merck & Co Inc	Piperazinylpyrimidine als beta-adrenergische Rezeptoren blockierende Mittel.
US4871739A (en) *	1987-01-21	1989-10-03	Merck & Co., Inc.	Substituted 6H-7,8-dihydrothiapyrano(3,2-D)-pyrimidines as hyopglycemic agents
US4889856A (en) *	1987-08-31	1989-12-26	Merck & Co., Inc.	7,8-dihydro-4-(1-pierazinyl)-6H-thiopyrano-[3,2-d] pyrimidines as β-blockers
JPH04224580A (ja)	1990-12-25	1992-08-13	Nippon Soda Co Ltd	ピリミジン誘導体、その製造方法及び農園芸用殺菌剤
DE19853278A1 (de) *	1998-11-19	2000-05-25	Aventis Pharma Gmbh	Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19904710A1 (de)	1999-02-05	2000-08-10	Aventis Pharma Gmbh	Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AP2003002762A0 (en)	2000-09-15	2003-03-31	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors
CA2423981A1 (en) *	2000-09-29	2003-03-28	Kimiko Ichikawa	Thienopyrimidine compounds and salts thereof and process for the preparation of the same
EP1474147B1 (en)	2001-12-07	2010-05-05	Vertex Pharmaceuticals Incorporated	Pyrimidine-based compounds useful as gsk-3 inhibitors
US7423044B2 (en) *	2002-09-05	2008-09-09	Wyeth	Pyrimidine derivatives useful in the treatment of insulin resistance and hyperglycemia
ES2217956B1 (es)	2003-01-23	2006-04-01	Almirall Prodesfarma, S.A.	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP4224580B2 (ja)	2003-02-28	2009-02-18	独立行政法人産業技術総合研究所	層状オルガノシリカナノ複合体およびその製造方法
US7223766B2 (en)	2003-03-28	2007-05-29	Scios, Inc.	Bi-cyclic pyrimidine inhibitors of TGFβ
EP1663994B1 (en) *	2003-08-05	2012-03-07	Vertex Pharmaceuticals Incorporated	Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels
TW200626157A (en) *	2004-09-30	2006-08-01	Tibotec Pharm Ltd	HCV inhibiting bi-cyclic pyrimidines

2005
- 2005-10-14 TW TW094135952A patent/TW200621257A/zh unknown
- 2005-10-17 US US11/577,648 patent/US7947690B2/en not_active Expired - Fee Related
- 2005-10-17 MX MX2007004769A patent/MX2007004769A/es not_active Application Discontinuation
- 2005-10-17 RU RU2007118653/04A patent/RU2007118653A/ru not_active Application Discontinuation
- 2005-10-17 JP JP2006542955A patent/JP4775767B2/ja not_active Expired - Fee Related
- 2005-10-17 ZA ZA200703947A patent/ZA200703947B/xx unknown
- 2005-10-17 BR BRPI0516237-8A patent/BRPI0516237A/pt not_active IP Right Cessation
- 2005-10-17 WO PCT/JP2005/019000 patent/WO2006043490A1/ja not_active Ceased
- 2005-10-17 CA CA2584666A patent/CA2584666C/en not_active Expired - Fee Related
- 2005-10-17 EP EP05793361A patent/EP1803710A4/en not_active Withdrawn
- 2005-10-17 AU AU2005297743A patent/AU2005297743A1/en not_active Abandoned
- 2005-10-17 CN CN2005800357323A patent/CN101044123B/zh not_active Expired - Fee Related
- 2005-10-17 KR KR1020077010353A patent/KR20070084035A/ko not_active Withdrawn
2007
- 2007-04-18 IL IL182641A patent/IL182641A0/en unknown
- 2007-05-18 NO NO20072542A patent/NO20072542L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20070084035A (ko)	2007-08-24
WO2006043490A1 (ja)	2006-04-27
BRPI0516237A (pt)	2008-08-26
CA2584666C (en)	2011-12-06
JP4775767B2 (ja)	2011-09-21
TW200621257A (en)	2006-07-01
US7947690B2 (en)	2011-05-24
IL182641A0 (en)	2007-07-24
US20080070896A1 (en)	2008-03-20
EP1803710A4 (en)	2009-08-26
EP1803710A1 (en)	2007-07-04
RU2007118653A (ru)	2008-11-27
ZA200703947B (en)	2008-08-27
MX2007004769A (es)	2007-06-25
CN101044123B (zh)	2010-09-08
CN101044123A (zh)	2007-09-26
JPWO2006043490A1 (ja)	2008-05-22
CA2584666A1 (en)	2006-04-27
AU2005297743A1 (en)	2006-04-27

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072542L (no)	2007-07-18	Pyrimidinderivat kondensert med ikke-aromatisk ring
WO2007082808A3 (en)	2007-09-13	Thiazoles as 11 beta-hsd1 inhibitors
NO20084321L (no)	2008-11-20	Triazolderivat eller salt derav
NO20084919L (no)	2009-01-20	Oksadiazolidindionforbindelse
WO2007107470A3 (en)	2007-11-08	Pyrazoles as 11-beta-hsd-1
NO20080164L (no)	2008-03-14	N-(pyridin-2-yl)-sulfonamidderivater
NO20073831L (no)	2007-09-11	Medikamenter for behandling eller forebygging av fibrotiske sykdommer
EP1806347A4 (en)	2009-07-01	PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
NO20080284L (no)	2008-03-07	Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
NO20074012L (no)	2007-10-08	1-tio-D-glucitolderivater
EA021275B9 (ru)	2015-08-31	Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
NO20085064L (no)	2009-02-06	4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20074872L (no)	2007-10-30	Pyrazoler
MX2007010532A (es)	2007-10-12	Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
DE602006009095D1 (en)	2009-10-22	Diacylglycerol-acyltransferase-hemmer
WO2010122980A8 (ja)	2011-02-17	新規甲状腺ホルモンβ受容体作動薬
HRP20120948T1 (hr)	2012-12-31	Derivati piridina koji su korisni kao aktivatori glukokinaze
NO20100301L (no)	2010-03-25	Forbedrete brimonidinsammensetninger for behandling av erytem
NO20084049L (no)	2008-10-20	Forbindelser med forsterket ampa receptor og anvendelse derav i medisin
AR047993A1 (es)	2006-03-15	Composicion farmaceutica que comprende pimobendano
NO20073830L (no)	2007-07-23	Medikamenter for behandling eller forebygging av fibrotiske sykdommer
NO20054396L (no)	2005-11-11	3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
NO20092763L (no)	2009-07-27	Isosorbid mononitrat derivater for behandling av tarmlidelser
GB2460784A (en)	2009-12-16	Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
NO20044091L (no)	2004-09-27	Anvendelse av substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on for fremstilling av medikamenter som inhiberer pankreatisk lipase